Viralgen and CTNNB1 Foundation partner to manufacture a new gene therapy for CTNNB1 Syndrome
Viralgen and the CTNNB1 Foundation have come together to manufacture an investigational gene therapy designed to treat CTNNB1 ...
Appointment of Joint Corporate Broker and Joint Financial Adviser
OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Jefferies International Limited ("Jefferies") as its Joint Corporate Broker and Joint ...